Melatonin and Benzodiazepine / Z Drug Abuse
Abstract: A temporal relationship between the nocturnal rise in melatonin secretion and the increase in sleep propensity at the beginning of the night, coupled with the sleeppromoting effects of exogenous melatonin, supports the view that melatonin is involved in the regulation of sleep. Both met...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Parte de libro |
| Lenguaje: | Inglés |
| Publicado: |
Springer Nature
2020
|
| Materias: | |
| Acceso en línea: | https://repositorio.uca.edu.ar/handle/123456789/10808 |
| Aporte de: |
| Sumario: | Abstract: A temporal relationship between the nocturnal rise in melatonin secretion and the
increase in sleep propensity at the beginning of the night, coupled with the sleeppromoting
effects of exogenous melatonin, supports the view that melatonin is
involved in the regulation of sleep. Both meta-analyses and consensus agreements
give credibility to the therapeutic use of melatonin in sleep disorders.
Administration of melatonin will cue the circadian phase of sleep/wake cycles in a
variety of disorders including jet lag problems, shift work maladaptation, advanced
and delayed sleep phase disorders, major affective disorder, seasonal affective
disorder and disrupted rhythms in attention deficit hyperactivity disorder, autism,
and schizophrenia. This action is attributed to MT1 and MT2 melatonin receptors
present in the hypothalamic suprachiasmatic nucleus (SCN) and in other brain
areas. Almost every single neuron in the SCN contains GABA and many results in
animals point out to a melatonin interaction with GABA-containing neurons. In
addition, central-type benzodiazepine (BZD) antagonism, that obliterates GABAA
receptor function, blunted melatonin behavioral effects including sleep. The sleep
promoting activity of melatonin is relevant because the BZD and type Z drugs
usually prescribed as sleep promoters have many adverse effects, such as next-day
hangover, dependence and impairment of memory. This Chapter discusses
available data on the efficacy of melatonin to curtail chronic BZD/ Z drug use in
insomnia patients. |
|---|